Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Collaborator: Oregon Health and Science University
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Clinical diagnosis of probable idiopathic Parkinson's Disease or no neurologic disease (no disease for controls only)

• At least 21 years of age

• Mini Mental Status Exam Score>=25

Exclusion Criteria:

• Evidence of psychosis (hallucinations or delusions) by history

• Any unstable medical condition

• Currently using dopamine blocking medication

• Currently taking anticoagulants or MAO inhibitors